Skip to content

Study · Not a test of the peptide alone · 2021

2 results

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination.

Chua MWJ

Clinics and practice21 Dec 2021Cited by 3 (Europe PMC)

PMID35076486 (opens in a new tab)PMCIDPMC8788265 (opens in a new tab)DOI10.3390/clinpract12010001 (opens in a new tab)PepBankPUB-35076486
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists are important drugs in our armamentarium of treatment for Type 2 diabetes mellitus (DM). In addition to their glucose-lowering effects, they have effects on weight, other metabolic diseases and perhaps most importantly, a cardioprotective and reno-protective effect. Liraglutide is a long-acting GLP-1 agonist which was originally used at 1.8 mg daily for the treatment of DM. However, high-dose liraglutide-liraglutide 3 mg daily, has been demonstrated to be a safe and effective treatment for obesity, with or without DM. In this manuscript, I present two patients who had unusual responses to combination therapy with high-dose liraglutide and SGLT2 inhibitor-marked and/or rapid improvement in glycemic control and weight loss. Drawing from the observations in both cases, I discuss the complementary mechanisms of actions of both drugs, review the clinical effects of combination therapy and distil them into clinical pearls of practical utility for the physician. Given the "clash of the two pandemics" of obesity and COVID-19 and the burgeoning rates of obesity which loom in the near horizon, this is most timely.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In two patients, combination therapy with high-dose liraglutide and an SGLT2 inhibitor was followed by marked or rapid improvement in glycemic control.

    In plain wordsIn two patients, taking high-dose liraglutide together with an SGLT2 inhibitor was followed by marked or rapid better blood sugar control.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedGlycemic control
    Study

    n = 2

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    In this manuscript, I present two patients who had unusual responses to combination therapy with high-dose liraglutide and SGLT2 inhibitor-marked and/or rapid improvement in glycemic control and weight loss.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In two patients, combination therapy with high-dose liraglutide and an SGLT2 inhibitor was followed by marked or rapid weight loss.

    In plain wordsIn two patients, taking high-dose liraglutide together with an SGLT2 inhibitor was followed by marked or rapid weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss
    Study

    n = 2

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    In this manuscript, I present two patients who had unusual responses to combination therapy with high-dose liraglutide and SGLT2 inhibitor-marked and/or rapid improvement in glycemic control and weight loss.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.